Prolia (Denosumab) Compounding Legal Status: What Patients and Prescribers Need to Know
Is compounded denosumab legal? Learn the FDA approval history, compounding restrictions, label requirements, and safety data for Prolia (denosumab) in one guide.
Denosumab: Regulatory History
8 source-based articles maintained by the HealthRX.com Editorial Team.
8articles
4topic areas covered
Jan 28, 2025latest review
Denosumab: Regulatory History library
Showing 8 of 8 clinical reviews.
Prolia (Denosumab) FAERS Safety Signals: Post-Market Surveillance Data and Clinical Implications
A comprehensive review of FDA Adverse Event Reporting System (FAERS) safety signals for Prolia (denosumab), including rebound vertebral fractures, atypical femoral fractures, hypocalcemia, and osteonecrosis of the jaw.
Prolia (Denosumab) FDA Approval History
A detailed regulatory timeline of denosumab (Prolia/Xgeva) from initial FDA approval through post-market safety updates, label expansions, and biosimilar developments.
Prolia (Denosumab) Global Regulatory Status: FDA Approval, Label Updates, and Post-Market Safety
Complete regulatory overview of denosumab (Prolia/Xgeva) covering FDA approval history, EMA authorization, boxed warning additions, REMS requirements, and global post-market surveillance findings.
Prolia (Denosumab) Label Updates 2020 to 2026: FDA Safety Changes, Boxed Warnings, and Post-Market Data
The FDA Prolia (denosumab) label, last revised March 2025, warns that stopping treatment raises fracture risk, including multiple vertebral fractures.
Prolia (Denosumab): EMA vs FDA Regulatory Approaches Compared
A side-by-side comparison of how the FDA and EMA regulate denosumab (Prolia/Xgeva), including approval timelines, label differences, post-market safety signals, and discontinuation guidance.
Prolia (Denosumab): FDA Pipeline, Label Updates, and Next-Generation Developments
Current 2026 review of the Prolia FDA label, severe hypocalcemia boxed warning, discontinuation risk, approved denosumab biosimilars, and treatment planning.
Prolia (Denosumab): Legal and Patent Challenges
A detailed review of the legal, patent, and regulatory challenges surrounding Prolia (denosumab), including FDA approval history, biosimilar competition, safety labeling updates, and post-market litigation.